JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monneret, G.
Right arrow Articles by Powell, W. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monneret, G.
Right arrow Articles by Powell, W. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL

Vol. 304, Issue 1, 349-355, January 2003

15R-Methyl-Prostaglandin D2 Is a Potent and Selective CRTH2/DP2 Receptor Agonist in Human Eosinophils

Guillaume Monneret1 , Chantal Cossette, Sylvie Gravel, Joshua Rokach and William S. Powell

Department of Medicine, Meakins-Christie Laboratories, McGill University, Montreal, Quebec, Canada (G.M., C.C., S.G., W.S.P.); and Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, Melbourne, Florida (J.R.)

Prostaglandin D2 (PGD2) is a mast cell-derived mediator that seems to play a role in asthma and allergic diseases. It is the only primary prostanoid to activate human eosinophils, which it accomplishes through the DP2 receptor/chemoattractant receptor-homologous molecule expressed on T helper cell type 2 (Th2) cells (CRTH2). In addition, PGD2 has both pro- and anti-inflammatory effects via the adenylyl cyclase-coupled DP1 receptor. To attempt to identify potent and selective DP2 receptor agonists we compared the abilities of a series of PGD2 analogs to activate eosinophils via the DP2 receptor with their abilities to stimulate adenylyl cyclase in platelets via the DP1 receptor. All of the PGD2 analogs tested stimulated CD11b expression and actin polymerization with a rank order of potency of 15R-methyl-PGD2 > PGD2 > 17-phenyl-18,19,20-trinor-PGD2 > 15S-methyl-PGD2 approx  16,16-dimethyl-PGD2 > 11-keto-fluprostenol. Surprisingly, 15R-methyl-PGD2, which has the unnatural R-configuration at carbon 15, was about 5 times more potent than PGD2 and about 75 times more potent than 15S-methyl-PGD2. 15R-methyl-PGD2 (EC50 value of 1.7 nM) was also much more potent as an eosinophil chemoattractant than PGD2 (EC50 value of 10 nM) and 15S-methyl-PGD2 (EC50 value of 128 nM). Cross-desensitization experiments indicated that 15R-methyl-PGD2 acts through the DP2 receptor. None of the PGD2 analogs tested elevated platelet cAMP by more than 20% of the maximal level in response to PGD2. However, in contrast to eosinophils, the most active was 15S-methyl-PGD2. In conclusion, 15R-methyl-PGD2 is the most potent known DP2 receptor agonist, and because of its selectivity and resistance to metabolism, should be a useful tool in probing the physiological role of this receptor in inflammatory diseases.

1 Current address: Flow Cytometry Unit, Immunology Laboratory, Lyon-Sud University Hospital, 69495 Pierre-Bénite, France.

0022-3565/03/3041-0349$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
R. Schroder, N. Merten, J. M. Mathiesen, L. Martini, A. Kruljac-Letunic, F. Krop, A. Blaukat, Y. Fang, E. Tran, T. Ulven, et al.
The C-terminal Tail of CRTH2 Is a Key Molecular Determinant That Constrains G{alpha}i and Downstream Signaling Cascade Activation
J. Biol. Chem., January 9, 2009; 284(2): 1324 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Rajakariar, T. Lawrence, J. Bystrom, M. Hilliard, P. Colville-Nash, G. Bellingan, D. Fitzgerald, M. M. Yaqoob, and D. W. Gilroy
Novel biphasic role for lymphocytes revealed during resolving inflammation
Blood, April 15, 2008; 111(8): 4184 - 4192.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Wada, C. J. DeLong, Y. H. Hong, C. J. Rieke, I. Song, R. S. Sidhu, C. Yuan, M. Warnock, A. H. Schmaier, C. Yokoyama, et al.
Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products
J. Biol. Chem., August 3, 2007; 282(31): 22254 - 22266.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Cossette, S. E. Walsh, S. Kim, G.-J. Lee, J. A. Lawson, S. Bellone, J. Rokach, and W. S. Powell
Agonist and Antagonist Effects of 15R-Prostaglandin (PG) D2 and 11-Methylene-PGD2 on Human Eosinophils and Basophils
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 173 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. M. Mathiesen, A. Christopoulos, T. Ulven, J. F. Royer, M. Campillo, A. Heinemann, L. Pardo, and E. Kostenis
On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2
Mol. Pharmacol., April 1, 2006; 69(4): 1441 - 1453.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. G. Trivedi, J. Newson, R. Rajakariar, T. S. Jacques, R. Hannon, Y. Kanaoka, N. Eguchi, P. Colville-Nash, and D. W. Gilroy
Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity
PNAS, March 28, 2006; 103(13): 5179 - 5184.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Chevalier, J. Stock, T. Fisher, M. Dupont, M. Fric, H. Fargeau, M. Leport, S. Soler, S. Fabien, M.-P. Pruniaux, et al.
Cutting Edge: Chemoattractant Receptor-Homologous Molecule Expressed on TH2 Cells Plays a Restricting Role on IL-5 Production and Eosinophil Recruitment
J. Immunol., August 15, 2005; 175(4): 2056 - 2060.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W. Almishri, C. Cossette, J. Rokach, J. G. Martin, Q. Hamid, and W. S. Powell
Effects of Prostaglandin D2, 15-Deoxy-{Delta}12,14-prostaglandin J2, and Selective DP1 and DP2 Receptor Agonists on Pulmonary Infiltration of Eosinophils in Brown Norway Rats
J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 64 - 69.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Spik, C. Brenuchon, V. Angeli, D. Staumont, S. Fleury, M. Capron, F. Trottein, and D. Dombrowicz
Activation of the Prostaglandin D2 Receptor DP2/CRTH2 Increases Allergic Inflammation in Mouse
J. Immunol., March 15, 2005; 174(6): 3703 - 3708.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Monneret, R. Boumiza, S. Gravel, C. Cossette, J. Bienvenu, J. Rokach, and W. S. Powell
Effects of Prostaglandin D2 and 5-Lipoxygenase Products on the Expression of CD203c and CD11b by Basophils
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 627 - 634.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.